Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Avastin Receives Add’l Indication for Breast Cancer: Chugai
October 10, 2011
- Onyx Submits NDA in US for Carfilzomib in MM: Ono
October 10, 2011
- Eisai, Abbott Japan File for Additional Indication for Humira
October 10, 2011
- CHMP Issues Positive Opinion on New ARB Edarbi: Takeda
October 10, 2011
- Takeda Aims at New Drug Development through Open Innovation
October 7, 2011
- Takeda to Offer Information on Actos for Prescribing Doctors
October 7, 2011
- Takeda US Unit Withdraw sNDA for Velcade
October 7, 2011
- Mediceo Aiming for 20% Market Share in Hokkaido within 3 Years: President Watanabe
October 7, 2011
- Eli Lilly Receives Positive Opinion from CHMP for Alimta as Maintenance Therapy for NSCLC
October 7, 2011
- Aiming for 6% Yearly Growth by Rivaroxaban Launching: Bayer AG
October 6, 2011
- Ranbaxy Starts Selling Daiichi Sankyo Drugs in Italy
October 6, 2011
- Eli Lilly Japan Applies for Approval of Fast-Acting Zyprexa Intramuscular Inj.
October 6, 2011
- Nihon Chouzai Introduces Catalog Retailing at All Its Stores
October 6, 2011
- Takeda President Hasegawa Says Innovation Will Take Place in Developing Countries
October 5, 2011
- Ono and Germany’s Merck Enter into License Agreements to Boost Priority Fields
October 5, 2011
- Rating Companies Downgrade Takeda following Acquisition of Nycomed
October 4, 2011
- Mochida’s New 3-Year Business Plan Aims for Sales of ¥100 Bil. in FY2013
October 4, 2011
- Shionogi Announces International Industry-Academic Collaboration Program
October 4, 2011
- Taisho HD Listed on 1st Section of Tokyo Stock Exchange with Closing Price of ¥6,750 on 1st Day of Trading
October 4, 2011
- Eisai Sets Up Aricept Dept. to Boost Japan Marketing Efforts
October 3, 2011
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…